Abstract: A chemical exposure indication device is disclosed. The device is removably attachable to a structure and includes a substrate having a first surface and a second surface and an indicating layer overlying the first substrate surface. The indicating layer includes a coating material that is chemically reactive with a pre-determined chemical compound that is known to degrade the structure. When the coating material is exposed to that corrosive compound in a pre-determined level associated with degradation of a metallic structure, the coating material provides a visual indication of the presence of the corrosive compound.

Abstract: A novel growth factor, fibroblast growth factor homologous factor-2 (FHF-2) polypeptide, the polynucleotide sequence encoding FHF-2 and the deduced amino acid sequence are disclosed. Also disclosed are diagnostic and therapeutic methods of using the FHF-2 polypeptide and polynucleotide sequences and antibodies which specifically bind to FHF-2.

Abstract: The invention disclosed relates to the biological production of substantially isomerically pure (R)-baclofen and structurally related compounds, from the racemic mixture of (R)- and (S)-isomers thereof, and to the isolation of a Streptomyces microorganism from Nature which is capable of preferentially metabolizing one of the isomers while showing minimal metabolic activity on the other isomer. A fermentation or bioconversion process using this microorganism or the cell-free enzymes derived therefrom for the biological resolution of a racemic mixture of (R)- and (S)-baclofen and structurally related compounds is also disclosed.

Abstract: Methods and compositions are described for treating contaminants in material intended for in vivo use, and in particular blood and blood products for human use. Contaminants in blood cell preparations are inactivated using 8-methoxypsoralen prior to long term storage and transfusion.

Abstract: Virginiamycin M.sub.1 having the Formula: ##STR1## and virginiamycin M.sub.1 analogs having the Formulae I-IV: ##STR2## Virginiamycin M.sub.1 and the analogs I-IV are antagonists of cholecystokinin (CCK) and gastrin. Cholecystokinin antagonists are useful as analgesics and in the treatment and prevention of disorders of the gastrointestinal, central nervous and appetite regulatory systems in animals, especially humans. Gastrin antagonists are useful in blocking the receptors for gastrin in humans and may function as agents for the treatment of ulcers, tumors or other gastrointestinal disorders. The compounds of Formulae I-IV are antibiotics and are useful as antimicrobial agents in animals including man and are useful as food additives to promote feed utilization in animals. Virginiamycin M.sub.1 and the analogs of Formula I, III and IV are produced by the controlled aerobic fermentation of a strain of Streptomyces olivaceus, ATCC No. 53527, while the analog of Formula II is produced by chemical synthesis.

Abstract: A shaped bacterial cell aggregate having increased hardness is produced by adding previously-produced dried finely-divided bacterial cell aggregate to bacterial cell aggregate subsequent to its formation but prior to its shaping.

Abstract: A novel antibiotic designated herein MM 17880 may be obtained from the cultivation of strains of Streptomyces olivaceus and related organisms. In addition to being potent antibacterial agents, MM 17880 and its salts inhibit .beta.-lactamase obtained from many organisms so that it shows a synergistic antibacterial effect when combined with .beta.-lactam antibiotics.

Abstract: It has been found that an antibiotic can be obtained by the fermentation of certain strains of Streptomyces olivaceus and related organisms and when pure this antibiotic is an extremely potent inhibitor of many .beta.-lactamases. This antibiotic which we designate MM 4550A may be obtained in substantially pure form by the chromatographic purification of the crude antibacterial complex obtained from the culture medium.